{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myeloid+Hematological+Malignancies&page=20", "query": { "condition": "Myeloid Hematological Malignancies", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 624, "total_pages": 63, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myeloid+Hematological+Malignancies&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myeloid+Hematological+Malignancies&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T06:31:17.695Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04644016", "title": "Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AML", "ALL", "MDS", "MPD Withou Myelofibrosis", "NHL or HL", "Inherited Metabolic Disorders", "Hemoglobinopathies", "Bone Marrow Failure", "HLH" ], "interventions": [ { "name": "Clofarabine", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclosporine-A", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Cord Blood Graft", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 31, "start_date": "2020-11-20", "completion_date": "2026-12-20", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-10-14T06:31:17.695Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644016" }, { "nct_id": "NCT01362179", "title": "National Marrow Donor Program Long-Term Donor Follow-Up", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hematologic Neoplasms" ], "interventions": [], "intervention_types": [], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 21974, "start_date": "2010-10", "completion_date": "2020-10-15", "has_results": false, "last_update_posted_date": "2020-10-20", "last_synced_at": "2026-10-14T06:31:17.695Z", "location_count": 28, "location_summary": "Duarte, California • Oakland, California • Santa Ana, California + 25 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01362179" }, { "nct_id": "NCT07346105", "title": "Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies", "overall_status": "AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Hematologic Malignancies", "Acute Myeloid Leukemia", "Acute Lymphoid Leukemia", "Myelodysplastic Syndrome", "Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Orca-T", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Orca Biosystems, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-14T06:31:17.695Z", "location_count": 8, "location_summary": "Los Angeles, California • Palo Alto, California • Tampa, Florida + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07346105" }, { "nct_id": "NCT04955938", "title": "A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "IDH Mutation", "IDH1 Mutation", "IDH2 Gene Mutation", "Blood Cancer", "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Ivosidenib", "type": "DRUG" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Fedratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-10-29", "completion_date": "2023-06-07", "has_results": false, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-14T06:31:17.695Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04955938" }, { "nct_id": "NCT07756034", "title": "Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Solid Tumor Cancer", "Pediatric Acute Myeloid Leukemia", "Hematologic Malignancies" ], "interventions": [], "intervention_types": [], "sponsor": "Tempus AI", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1000, "start_date": "2026-08", "completion_date": "2031-07", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-14T06:31:17.695Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07756034" }, { "nct_id": "NCT04318678", "title": "CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML/MDS", "B-ALL", "T-ALL", "BPDCN" ], "interventions": [ { "name": "CD123-CAR T", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 108, "start_date": "2020-07-29", "completion_date": "2030-07-29", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-14T06:31:17.695Z", "location_count": 2, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04318678" }, { "nct_id": "NCT01231919", "title": "MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Acute Leukemias of Ambiguous Lineage", "Acute Myeloid Leukemia/Transient Myeloproliferative Disorder", "Acute Undifferentiated Leukemia", "Aggressive NK-cell Leukemia", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Blastic Phase Chronic Myelogenous Leukemia", "Blastic Plasmacytoid Dendritic Cell Neoplasm", "Childhood Burkitt Lymphoma", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Grade III Lymphomatoid Granulomatosis", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Intraocular Lymphoma", "Juvenile Myelomonocytic Leukemia", "Mast Cell Leukemia", "Myeloid/NK-cell Acute Leukemia", "Noncutaneous Extranodal Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Primary Central Nervous System Hodgkin Lymphoma", "Primary Central Nervous System Non-Hodgkin Lymphoma", "Progressive Hairy Cell Leukemia, Initial Treatment", "Prolymphocytic Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "Akt inhibitor MK2206", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 45, "start_date": "2011-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-04-29", "last_synced_at": "2026-10-14T06:31:17.695Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01231919" }, { "nct_id": "NCT06131801", "title": "Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hematologic Malignancy", "Leukemia", "Lymphoma", "Acute Lymphocytic Leukemia", "ALL", "Acute Myelogenous Leukemia", "AML", "Chronic Myelogenous Leukemia", "CML", "Myeloproliferative Neoplasm", "Non Hodgkin Lymphoma", "Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma", "Follicular Lymphoma", "Burkitt Lymphoma", "T-cell Lymphoma", "B Cell Lymphoma", "Peripheral T Cell Lymphoma", "Cutaneous B-Cell Lymphoma" ], "interventions": [ { "name": "1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "38 Years", "sex": "ALL", "summary": "0 Years to 38 Years" }, "enrollment_count": 30, "start_date": "2023-11-15", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-14T06:31:17.695Z", "location_count": 6, "location_summary": "Aurora, Colorado • Atlanta, Georgia • Cincinnati, Ohio + 3 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06131801" }, { "nct_id": "NCT00726830", "title": "Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Pain", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "methadone hydrochloride", "type": "DRUG" }, { "name": "morphine sulfate", "type": "DRUG" }, { "name": "oxycodone hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2009-03", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-10-14T06:31:17.695Z", "location_count": 2, "location_summary": "Spartanburg, South Carolina • Houston, Texas", "locations": [ { "city": "Spartanburg", "state": "South Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00726830" }, { "nct_id": "NCT06034275", "title": "Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "B-cell Acute Lymphoblastic Leukemia", "High-risk Myelodysplastic Syndrome" ], "interventions": [ { "name": "VIP943 (QW)", "type": "DRUG" }, { "name": "VIP943 (BIW)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vincerx Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2023-09-13", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-10-14T06:31:17.695Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Cincinnati, Ohio • Nashville, Tennessee + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06034275" } ] }